Incorporation of lycopene into chylomicron remnant-like particles inhibits their uptake by HepG2 cells.
The influence of the incorporation of the antioxidant tomato pigment, lycopene, into chylomicron remnant-like particles (CRLPs) on their uptake by the liver cells was investigated. CRLPs or CRLPs containing lycopene (lycCRLPs) radiolabelled with [(3)H]triacylglycerol were incubated with cells of the human liver hepatoma cell line, HepG2, and the radioactivity taken up by the cells was determined. LycCRLPs were taken up significantly more slowly than CRLPs over a concentration range of 5-60 microg cholesterol/ml and a time course of 2-6 h. Pre-incubation of the hepatocytes with an excess of low density lipoprotein (LDL) inhibited the uptake of CRLPs by about 50%, but had no effect on the uptake of lycCRLPs, and under these conditions the CRLPs and lycCRLPs were taken up at similar rates. In HepG2 cells pre-treated with suramin, which inhibits uptake via the LDL receptor-related protein (LRP), the uptake of CRLPs was also inhibited (-37%) to a greater extent than that of lycCRLPs (-24%), so that the values for the two types of particle were no longer significantly different. Heparinase increased the uptake of lycCRLPs (about 2 fold), but not CRLPs, bringing it to a level equivalent to that seen with the control particles. These findings demonstrate that the incorporation of lycopene into CRLPs decreases their uptake by HepG2 cells and suggest that this effect is due to differential interaction with the LDL receptor and the LRP-receptor-mediated pathways, and may also involve binding of the particles to HSPG.
Bejta
Fatos
F
Department of Veterinary Sciences, The Royal Veterinary College, London, UK.
Napolitano
Mariarosaria
M
Botham
Kathleen M
KM
Bravo
Elena
E
D000969:Antinematodal Agents / Q000494:pharmacology; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology*; D002338:Carotenoids / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D053298:Chylomicron Remnants / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D019763:Heparin Lyase / Q000494:pharmacology; D022781:Hepatocytes / Q000378:metabolism*; D006801:Humans; D008077:Lipoproteins, LDL / Q000494:pharmacology; D000077276:Lycopene; D011973:Receptors, LDL / Q000378:metabolism*; D013498:Suramin / Q000494:pharmacology
D000969:Antinematodal Agents; D000975:Antioxidants; D053298:Chylomicron Remnants; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; D002338:Carotenoids; D013498:Suramin; D019763:Heparin Lyase; D000077276:Lycopene